The Shift from Devices to Solutions and the Three Ds
First written in FY2022. 5 of 6 entries say "Advanced", first in FY2023. Latest entry: FY2026.
3 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「Heart (coronary) 80%; lower-limb arteries 6%; abdomen 17%; cerebrovascular 15%」
Disclosed FY2025 actual radial access rates against the FY2026 targets. The heart/coronary rate exceeded the target of 75% or higher, while the abdominal rate exceeded 15% or higher and the cerebrovascular rate exceeded 15% or higher. The lower-limb artery rate remained below the target of 20% or higher. - 2026-05-15AdvancedEarnings
「Even in the current fiscal year, the final year of the five-year growth strategy GS26, we will address challenges in the healthcare field, including shortages of healthcare professionals and efforts to improve the efficiency of hospital operations, and seek to achieve the targets set out in the growth strategy by expanding and creating businesses that provide new value and solutions.」
The Company indicated that it would continue expanding and creating solution businesses addressing challenges in the healthcare field during the final year of GS26. - FY2025AdvancedAnnual report
「Heart (coronary) 79%; lower-limb arteries 8%; abdomen 15%; cerebrovascular 12%」
Disclosed FY2024 actual radial access rates under GS26. The coronary rate exceeded the FY2026 target of 75% or higher, and the abdominal rate reached its target of 15%, while the rates for lower-limb arteries and cerebrovascular procedures remained below target. - FY2024AdvancedAnnual report
「Heart (coronary) 73%; lower-limb arteries 5%; cancer treatment 9%; cerebrovascular 8%」
Disclosed FY2023 actual radial access rates against the FY2026 targets under GS26’s “From Devices to Solutions” direction. The coronary rate was 73%, versus a target of 75% or higher, while the rates for lower-limb arteries, cancer treatment and cerebrovascular procedures were 5%, 9% and 8%, respectively. - FY2023AdvancedAnnual report
「Radial access rate (FY2026): Heart (coronary) 75% or higher; lower-limb arteries 20% or higher; cancer treatment 15% or higher; cerebrovascular 15% or higher」
Developed GS26’s “From Devices to Solutions” direction into specific strategies, including the FY2026 target radial access rates, 100% minimally invasive treatment, a 100% treatment completion rate and the integration of digital technologies, devices and drugs. - FY2022First statedAnnual report
「Terumo positioned GS26 as a five-year growth strategy looking beyond the next 10 years and set out its vision as “From Devices to Solutions.” Specifically, it will pursue the three “Ds”: Delivery, Digital and, finally, Deviceuticals.」
Identified the new business vision under GS26 for the first time. Centered on Delivery, Digital and Deviceuticals, the company set out a transition from standalone devices to solutions incorporating combinations with treatments, diagnostics and drugs. As long-term goals, it presented 100% minimally invasive treatment, a 100% treatment completion rate and the evolution of combination products.